"OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo.

Micellar nanoparticles based on linear polyethylene glycol (PEG) block dendritic cholic acids (CA) copolymers (telodendrimers), for the targeted delivery of chemotherapeutic drugs in the treatment of cancers, are reported. The micellar nanoparticles have been decorated with a high-affinity "OA02" peptide against α-3 integrin receptor to improve the tumor-targeting specificity which is overexpressed on the surface of ovarian cancer cells. "Click chemistry" was used to conjugate alkyne-containing OA02 peptide to the azide group at the distal terminus of the PEG chain in a representative PEG(5k)-CA(8) telodendrimer (micelle-forming unit). The conjugation of OA02 peptide had negligible influence on the physicochemical properties of PEG(5k)-CA(8) nanoparticles and as hypothesized, OA02 peptide dramatically enhanced the uptake efficiency of PEG(5k)-CA(8) nanoparticles (NP) in SKOV-3 and ES-2 ovarian cancer cells via receptor-mediated endocytosis, but not in α-3 integrin-negative K562 leukemia cells. When loaded with paclitaxel, OA02-NPs had significantly higher in vitro cytotoxicity against both SKOV-3 and ES-2 ovarian cancer cells as compared with nontargeted nanoparticles. Furthermore, the in vivo biodistribution study showed OA02 peptide greatly facilitated tumor localization and the intracellular uptake of PEG(5k)-CA(8) nanoparticles into ovarian cancer cells as validated in SKOV3-luc tumor-bearing mice. Finally, paclitaxel (PTX)-loaded OA02-NPs exhibited superior antitumor efficacy and lower systemic toxicity profile in nude mice bearing SKOV-3 tumor xenografts, when compared with equivalent doses of nontargeted PTX-NPs as well as clinical paclitaxel formulation (Taxol). Therefore, OA02-targeted telodendrimers loaded with paclitaxel have great potential as a new therapeutic approach for patients with ovarian cancer.

[1]  Eva Harth,et al.  Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. , 2010, Cancer research.

[2]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[3]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[4]  J. Kreidberg.  Functions of α3β1 integrin , 2000 .

[5]  K. Lam,et al.  A novel size-tunable nanocarrier system for targeted anticancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Gerd Ritter,et al.  PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. , 2008, ACS nano.

[7]  Li Wang,et al.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. , 2009, Biomaterials.

[8]  Kit S Lam,et al.  Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. , 2011, Biomaterials.

[9]  Thommey P. Thomas,et al.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.

[10]  Kit S Lam,et al.  Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. , 2010, Bioconjugate chemistry.

[11]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Jian-hui Jiang,et al.  Aptamer-modified nanodrug delivery systems. , 2011, ACS nano.

[13]  Ruiwu Liu,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging , 2006 .

[14]  D. Friedland,et al.  Hypersensitivity reactions from taxol and etoposide. , 1993, Journal of the National Cancer Institute.

[15]  Kit S Lam,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. , 2006, Nature chemical biology.

[16]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[17]  R. Weissleder,et al.  Multivalent effects of RGD peptides obtained by nanoparticle display. , 2006, Journal of medicinal chemistry.

[18]  Yan Guo,et al.  Novel peptide ligand directs liposomes toward EGF‐R high‐expressing cancer cells in vitro and in vivo , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  P. McCarron,et al.  Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. , 2008, Bioconjugate chemistry.

[20]  Paclitaxel (taxol) for ovarian cancer. , 1993, The Medical letter on drugs and therapeutics.

[21]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[22]  Bo Yu,et al.  Receptor-targeted nanocarriers for therapeutic delivery to cancer , 2010, Molecular membrane biology.

[23]  Kit S Lam,et al.  Near-Infrared Optical Imaging of Ovarian Cancer Xenografts with Novel α3-Integrin Binding Peptide “OA02” , 2005, Molecular imaging.

[24]  M. Shoichet,et al.  Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. , 2009, Bioconjugate chemistry.

[25]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[26]  J. Kreidberg.  Functions of alpha3beta1 integrin. , 2000, Current opinion in cell biology.

[27]  Xiaoyuan Chen,et al.  Integrin Targeted Delivery of Chemotherapeutics , 2011, Theranostics.

[28]  Jun Chen,et al.  Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. , 2009, Cancer research.

[29]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[30]  Kit S Lam,et al.  PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[32]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[33]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Hyesung Jeon,et al.  Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[36]  Si-Shen Feng,et al.  Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. , 2007, Biomaterials.

[37]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[38]  Abby M. Gonik,et al.  The passive targeting of polymeric micelles in various types and sizes of tumor models , 2010 .

[39]  Yin Ren,et al.  In vivo tumor cell targeting with "click" nanoparticles. , 2008, Bioconjugate chemistry.

[40]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  Ronald C. Chen,et al.  Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. , 2011, ACS nano.

[42]  G. Mizejewski,et al.  Role of integrins in cancer: survey of expression patterns. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.